Peptide Research Week in Review: 25-31 October 2026

What Happened in Peptide Research This Week (25-31 Oct 2026)?

Two stories dominated. On 28 October, Eli Lilly announced positive topline results from TRANSCEND-T2D-2, a Phase 3 head-to-head trial of its investigational triple agonist retatrutide against semaglutide 2 mg.[1] In the same days Lilly published third-quarter 2026 results that listed that readout among its highlights.[3] Separately, on 28 October the US Department of Health and Human Services announced an enforcement-discretion policy on compounding six peptides, a story that drew immediate criticism from FDA scientists, according to the Associated Press.[5]

Everything below is third-party reporting on pharmaceutical, academic and regulatory activity. It does not describe, or endorse, any use of research reagents outside the laboratory. For the previous digest, see Peptide Research Week in Review: 18-24 October 2026.

What Did Lilly Report for Retatrutide This Week?

Lilly described TRANSCEND-T2D-2 as a Phase 3 comparison of retatrutide (LY3437943) with injectable semaglutide 2 mg in adults with type 2 diabetes. The registry entry is NCT06260722.[1][2] In its release, Lilly reported that retatrutide lowered A1C by an average of 2.2 percentage points against 1.8 for semaglutide 2 mg at 80 weeks.[1] These are sponsor-reported topline values. We could not retrieve the full release or any peer-reviewed paper, and the dose-by-dose tables, sample size and safety detail were not available to us.

For the design, endpoints and caveats, see our dedicated summaries: TRANSCEND-T2D-2 vs semaglutide and the Ozempic comparison. For compound specifications only, the research-grade retatrutide page lists purity and format.

What Did Lilly's Third-Quarter Release Say About Timelines?

Search-indexed coverage of the release reports revenue up 39% to $24.4 billion and raised full-year guidance, with the retatrutide head-to-head result listed among the highlights.[3] We did not find, and could not verify, any new statement of retatrutide submission timing in the third-quarter materials. The most recent confirmed company position remains the second-quarter statement: the clinical data package is complete and a US submission is planned for the first quarter of 2027, with manufacturing documentation still being finalised.[4] Sources also disagree on whether the release and call fell on 28 or 29 October, so we cite both rather than choose one.

The legal classification dispute over retatrutide is a separate track, and we found no ruling reported this week. Our Q3 earnings preview and filing-delay guide set out what is known and what is open.

What Did HHS Announce About Compounded Peptides?

On 28 October 2026 HHS announced a policy under which it says it will not take enforcement action against certain compounding of six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, subject to stated conditions.[6][7] Outlets differ on whether the document is a draft or a final policy, so the Federal Register text, not a summary, is the authority.[7] The Associated Press reported that FDA scientists opposed the effort, and trade outlets describe the policy as a bridge ahead of formal 503A rulemaking, which is reported to take 12 to 24 months.[5][6]

Enforcement discretion is neither a marketing approval nor a bulks-list listing, and it can be withdrawn. Our full explainer covers the conditions reported and the three regulatory mechanisms. Earlier context sits in the OMB review guide.

How Should Researchers Read This Week's News?

Keep three categories apart. First, licensed pharmaceutical development: retatrutide is an investigational Lilly compound, studied in regulated, ethics-approved trials with medical supervision, and nothing in a topline press release transfers to a laboratory reagent. Second, US regulatory process: a compounding policy governs pharmacies, not research suppliers. Third, research-use compounds handled in vitro, where the questions are receptor pharmacology, identity and purity. Our retatrutide mechanism of action guide summarises the published receptor work, and the injectable peptide evidence review explains why the human evidence for most non-approved peptides remains thin.

What Should Researchers Watch Next?

Four items. A conference presentation or journal publication of TRANSCEND-T2D-2 with full tables; Lilly's retatrutide submission timing against the Q1 2027 target; the Federal Register status and any comment period for the HHS peptide policy; and any appellate ruling on retatrutide's classification. We found no MHRA or ASA announcement relevant to these compounds this week.

Does This Week's News Change UK Research-Reagent Supply?

No. Retatrutide has no marketing authorisation from the FDA, MHRA or any regulator, and US compounding policy does not govern UK research-reagent supply. Velox Peptides supplies retatrutide strictly as an HPLC-verified research reagent, with no health or therapeutic claims. Researchers should verify any reagent against its certificate of analysis.

This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions